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Intracellular sodium elevation reprograms cardiac
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Intracellular Na elevation in the heart is a hallmark of pathologies where both acute and
chronic metabolic remodelling occurs. Here, we assess whether acute (75 μM ouabain 100
nM blebbistatin) or chronic myocardial Nai load (PLM3SA mouse) are causally linked to
metabolic remodelling and whether the failing heart shares a common Na-mediated meta-
bolic ‘fingerprint’. Control (PLMWT), transgenic (PLM3SA), ouabain-treated and hyper-
trophied Langendorff-perfused mouse hearts are studied by 23Na, 31P, 13C NMR followed by
1H-NMR metabolomic profiling. Elevated Nai leads to common adaptive metabolic alterations
preceding energetic impairment: a switch from fatty acid to carbohydrate metabolism and
changes in steady-state metabolite concentrations (glycolytic, anaplerotic, Krebs cycle
intermediates). Inhibition of mitochondrial Na/Ca exchanger by CGP37157 ameliorates the
metabolic changes. In silico modelling indicates altered metabolic fluxes (Krebs cycle, fatty
acid, carbohydrate, amino acid metabolism). Prevention of Nai overload or inhibition of Na/
Camito may be a new approach to ameliorate metabolic dysregulation in heart failure.
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In the heart, the Na/K ATPase plays a crucial role in trans-membrane transport, ion homeostasis, electrical excitability,control of cell volume and contractility1. The activity of the
Na/K ATPase is regulated by FXYD1, or phospholemman (PLM),
the principal sarcolemmal substrate of protein kinases A and C2,3.
PLM is required for the dynamic control of intracellular sodium
(Nai) during increases in heart rate and plays a vital role in Nai
regulation during ‘fight or flight’1. More recent studies have
suggested that cytosolic Nai regulation also plays an important
role in linking mitochondrial Ca-dependent ATP production to
mechanical activity and ATP demand4–6. Increases in cardiac
contractility are largely driven by increases in the cytosolic Ca
transient which, in turn, is sensed by mitochondria to ensure that
ATP supply matches consumption7. In the mitochondria, a rise in
matrix calcium (Camito) activates the F1F0 ATPase (complex V of
mitochondrial respiratory chain)8, and several Ca sensitive
dehydrogenases (CaDHmito), including pyruvate dehydrogenase
(PDH), α-ketoglutarate dehydrogenase and the NAD-linked iso-
citrate dehydrogenase (IDH3)9. CaDHmito activation of the Krebs
cycle results in increased NADH production, which is critical to
supply reducing equivalents for the electron transport chain
(ETC), free radical (ROS) regulation and redox signalling5. This
crucial ATP supply-demand relationship has been proposed to be
affected by elevated cytosolic Nai, which activates Na/Ca
exchange in the inner mitochondrial membrane (NCLX),
decreasing Cam and leading to impaired NADH/NAD+ redox
cycling and metabolic inefficiency3,4. In addition to the link with
mitochondrial metabolism, the high turnover of ATP required for
Na/K ATPase function has been reported to be tightly coupled to
ATP supply arising preferentially from glycolysis10,11 providing
further evidence for a link between cytosolic Na ion homeostasis
and metabolism.
The rise of Nai in cardiac pathologies such as heart failure may
be due in part to elevated late Na current12, diastolic Na influx via
Na channels13 and/or reduced NKA function1. Cardiac hyper-
trophy and failure are characterized by elevated Nai14,15, meta-
bolic insufficiency, increased ROS production and changes in
myocardial substrate preference with a shift from dominant fatty
acid oxidation towards carbohydrate oxidation16. The extent that
these changes reflect chronic cellular remodelling, or arise as a
consequence of the accompanying Nai elevation, has not been
determined. Whether chronic Nai elevation, Nai elevation in
hypertrophy or acute Nai elevation share a common metabolic
‘fingerprint’, and the details of the metabolic derangements
involved also remain largely unknown. The aims of the current
study are (i) to determine the detailed metabolic changes asso-
ciated with chronic Na/K ATPase inhibition in the PLM3SA
mouse, during cardiac hypertrophy (aortic constriction) and
following acute pharmacological Nai elevation, (ii) to dissociate
such changes from the increased inotropic state (and hence
metabolic demand) that occurs with Nai elevation and (iii) to
determine whether chronic or acute Na driven changes in
metabolism can be reversed by pharmacologically inhibiting
mitochondrial NCLX.
We use nuclear magnetic resonance spectroscopy (NMR) to
assess Nai (multiple quantum filtered 23Na NMR) and energetics
(31P NMR) in real time in isolated perfused mouse hearts. Sub-
strate preference is determined using 13C NMR and steady-state
metabolomic profile is performed using high-resolution 1H NMR,
LC and GC/MS spectrometry. We observe that there are common
Na-dependent metabolic alterations in chronic Na/K ATPase
inhibition (PLM3SA mouse), cardiac hypertrophy and in response
to acute Nai elevation (ouabain). The phenotypes are char-
acterised by a switch in substrate preference from fatty acid to
carbohydrate oxidation. However, Krebs cycle fluxes are identi-
fied as compensated by in silico modelling while, in the absence of
elevated inotropy, neither chronic nor acute Nai elevation results
in energetic impairment (PCr/ATP) suggesting this to be an
adaptive response. The metabolic changes are acutely reversed by
inhibiting mitochondrial Na/Ca exchange suggesting a causal link
between Nai elevation and adaptive metabolic remodelling that
ensues.
Results
Chronic Na elevation alters cardiac metabolic profile in
PLM3SA. We have used multiple quantum filtered (TQF) 23Na
NMR spectroscopy to measure intracellular Na in Langendorff-
perfused hearts. In the isolated heart, the TQF signal is a com-
posite arising from the sum of various compartments, each with
varying electrostatic interactions, Na concentrations, and volumes
occupied17. In order to define the subcellular origin of this signal
we have assessed the relative contribution of subcellular com-
partments to the total 23Na TQF signal (Supplementary Fig. 1).
We estimated the following compartmental contributions to the
TQF signal: Vascular+ extracellular space= 47%. Intracellular
signal= 53%, Cytoplasmic signal= 44%, Mitochondrial signal=
9% (Supplementary Note 1).
Using 23Na TQF NMR, we have previously shown that Nai is
chronically elevated in hearts from PLM3SA mice by ~20–40%
compared to WT17, consistent with an increase in the Km for Nai
activation of the cardiac Na/K ATPase17. Therefore, we first
sought to investigate whether basal cardiac metabolism is altered
in the PLM3SA mouse heart and whether there is a potential link
to the elevated Nai seen in this model. Despite a small alteration
in serum glucose and insulin concentration in PLM3SA mice
(Supplementary Table 2), there was no functional consequence
because glucose tolerance tests, glucose transporter expression
(GLUT1 and GLUT4) and the skeletal muscle metabolic
phenotype (fed and fasted state Supplementary Fig. 2) were
comparable between the two genotypes.
Comprehensive metabolic assessment of PLM3SA excluded
changes in systemic metabolic confounders (circulating metabo-
lites and hormones), liver dysfunction, muscle damage and
mitochondrial organization (Supplementary Figs. 2, 3, Supple-
mentary Table 2). There was no difference in the protein
expression of IDH3, Ca-sensitive rate determining enzyme of the
Kreb’s cycle, between the groups (PLM3SA 1.0 ± 0.05 vs 1.0 ± 0.07
AU PLMWT n= 7/group, Supplementary Fig. 4) and expression
of pyruvate dehydrogenase (PLM3SA 1.03 ± 0.1 vs 1 ± 0.08
PLMWT n= 7/group, Supplementary Fig. 4).
Furthermore, there were no differences in ex vivo function
between WT and PLM3SA mouse hearts paced at 550 beats min−1
(LVDP, HR, coronary flow) or non-paced hearts (Supplementary
Fig. 5) in agreement with previous in vivo observations in the
same model18. Previous studies indicate an absence of inotropic
changes in PLM3SA mouse hearts, despite the elevation of
intracellular Na18, which is potentially driven by adaptations in
sarcolemmal Na regulatory protein expression (NCX and PLM/
Na/K ATPase α2 subunit).
Given the lack of overt systemic metabolic phenotype in
PLM3SA we next performed 13C NMR analysis of substrate
contribution to oxidative metabolism, revealing a switch in
substrate preference from fatty acid to glucose oxidation
(Fig. 1a). 1H NMR metabolite analysis of extracted heart
tissue revealed a significant global depletion of energy
providing substrates including lactate, amino acids (aspartate,
glutamine, glutamate, alanine, glycine), intermediates of
Krebs cycle (citrate, succinate) and constituents of lipid
metabolism (phosphocholine, acetyl carnitine, acetate) (Fig. 1c).
PLM3SA hearts did not display a compromised PCr/ATP ratio
which was the same as their WT counterpart (Fig. 1e)
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indicating that the switch from fatty acid to glucose oxidation
and depletion of metabolic intermediates is adaptive. To
explore whether the metabolic alterations in this model were
causally linked to the elevation in Nai we next explored the
influence of inhibiting NCLX. Treatment with 1μM CGP37157
was without effect in wild-type mice but had a significant effect
on the altered cardiac metabolic profile in transgenic PLM3SA
hearts. It normalized concentrations of depleted metabolic
intermediates (Fig. 1g) and normalized rates of PLM3SA
palmitate oxidation vs. WT controls (Fig. 1a), thus reverting
the glucose-palmitate substrate switch in 30 min of exposure. In
the absence of systemic metabolic derangement (whole body-
muscle, liver, serum etc), hypertrophy, cardiac dysfunction or
increased inotropy, our data suggest that chronic Nai elevation
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(PLM3SA vs PLMWT) leads to significant changes in myocardial
metabolism.
Chronic Na elevation alters metabolism in cardiac hyper-
trophy. We next sought to establish whether the chronic altera-
tions in metabolism seen in the PLM3SA mouse are recapitulated
in pathological hypertrophy. Myocardial hypertrophy was
induced in C57BL/6J mice by pressure overload following supra-
renal aortic constriction (banding) for 5 weeks (Fig. 2a, Supple-
mentary Table 3). Cardiac hypertrophy was associated with a
significant decline in in vivo function (Supplementary Table S3)
and, as previously demonstrated, a 40% increase in myocardial
Nai15. There was no evidence of heart failure or cardiac decom-
pensation as indicated by the absence of pulmonary oedema
(Supplementary Table 3). Ex vivo function of unpaced hyper-
trophied hearts was not significantly different to sham controls.
Consistent with previous studies, we found that LVDP was
impaired when hearts were paced at higher heart rates (550 beats
m−1)18. 13C NMR analysis of substrate contribution to oxidative
metabolism revealed that pressure overload hypertrophy was also
associated with a switch in substrate preference from fatty acid to
glucose oxidation (Fig. 2b) as previously shown19, while the
contribution of pyruvate, lactate and endogenous substrates was
decreased. As to the PLM3SA data, tissue NAD, PCr, aspartate
and alanine concentrations were increased while all other mea-
sured metabolite concentrations were unchanged compared to
sham (Krebs cycle, intermediates, lipid and amino acid metabo-
lism constituents) (Fig. 2c). Further, the intracellular PCr/ATP
ratio was preserved (PCr/ATP Banded 1.17 ± 0.07 vs Sham 1.21 ±
0.18 n= 5/group) suggesting that metabolic remodelling in the
heart remains adaptive after five weeks of pressure-overload
induced hypertrophy. We next explored whether the metabolic
alterations observed in hypertrophy might also be linked to the
elevation in Nai via the action of NCLX. Treatment with 1 μM
CGP37157 also had a significant effect on substrate preference in
hypertrophic hearts, leading to an increase in palmitate oxidation
and a decrease in glucose oxidation, thus reverting the glucose-
palmitate substrate switch (Fig. 2b). 1-μM CGP37157 treatment
had a less pronounced effect on the steady-state metabolite profile
in the hypertrophy group due to the more subtle changes
observed in this group (Fig. 2d).
Acute Nai elevation alters cardiac metabolic profile without
compromising energetics. Acute pharmacological inhibition of
Na/K ATPase in wild-type (WT) mouse hearts using ouabain
(Ouab) caused a 140% increase in intracellular Na (Fig. 3a) and an
associated 70% increase in LVDP within 30min (Fig. 3b). Myocyte
protein expression (IDH3, pyruvate dehydrogenase) was not
altered following 30mins of drug treatment (Supplementary
Fig. 4). Central to our hypothesis, and to be consistent with the
PLM3SA and hypertrophy groups, the direct effects of Nai on
cardiac metabolism need to be assessed independently of changes
in inotropy and energy demand. Accordingly, in pilot experiments,
we defined a concentration of 100 nmol l−1 for the myofilament
uncoupler blebbistatin (Blebbi) that, when simultaneously perfused
with ouabain, was sufficient to antagonise the positive inotropy
without itself causing a negative inotropy. The inotropically neutral
combination of 75 μmol l−1 ouabain and 100 nmol l−1 blebbistatin
was then used throughout in ex vivo mouse heart experiments.
None of the pharmacological combinations affected heart rate
(Fig. 3c) or coronary flow (Fig. 3d) over the 50min course of
perfusion. 13C NMR analysis of substrate contribution to oxidative
metabolism also revealed that acute ouabain/blebbistatin treatment
resulted in reduced oxidation of fatty acids in relation to the
contribution of other fuels, principally carbohydrates (glucose,
pyruvate, lactate) (Fig. 4a). Acute Na elevation also resulted in
increased levels of lactate and isocitrate, as well as the big drop-off
in metabolite levels of Krebs cycle intermediates downstream from
α-ketoglutarate dehydrogenase (succinate, fumarate, malate,
Fig. 4b). These effects are consistent with reduced Ca-dependent
activation of the critical Krebs cycle dehydrogenases at these
points.
Using 1H NMR and GC- and LC-MS/MS metabolomic
profiling, we identified extensive metabolic changes in intermediary
metabolites including the Krebs cycle, oxidative phosphorylation,
glycolysis and anaplerosis (Fig. 4b) that was more pronounced than
that observed in the PLM3SA group. Acute Nai elevation, in the
absence of any change in inotropy did not compromise myocardial
energetics (PCr/ATP ratio, Fig. 4c). Lowering contractility below
baseline with Blebbi alone resulted in a modest PCr/ATP elevation
(Fig. 4c). Treatment with 1-μM CGP37157 had a significant effect
on cardiac metabolic profile during acute Nai elevation, normal-
izing the concentrations of metabolic intermediates previously seen
to be depleted (Fig. 4d). In the absence of increased inotropy, our
data suggest that acute Nai elevation leads to significant changes in
myocardial metabolism.
In silico modelling reveals common Na-induced metabolic
changes. To assess the impact of Nai on cardiac metabolism at a
systems scale, we conducted mathematical modelling using Car-
dioNet20,21. CardioNet has been successfully applied to identify
limiting metabolic processes and estimate flux distributions22. We
determined flux distributions using flux balance analysis (FBA),
which seeks to determine flux rates during steady-state while
optimising an objective function (see Supplementary Methods for
Fig. 1 Metabolic profile of PLM3SA and PLMWT hearts. a Myocardial 13C NMR assessment of oxidative metabolism—% contribution of 13C-U palmitate,
13C 1,6 glucose and the remnant unlabelled 13C substrate pool (triglycerides, glycogen, pyruvate, lactate, ketone bodies). 13C NMR assessment of oxidative
metabolism after 30min administration of CGP37157 in 13C-KHmetab buffer—PLM3SA (n= 6) vs PLMWT (n= 7) hearts. (*P < 0.03 PLM3SA palmitate
oxidation vs PLMWT, P < 0.02 PLM3SA glucose oxidation vs PLMWT, t= 3.7 df= 8). b Representative 13C spectrum from perfused mouse heart: full 13C
glutamate spectrum. Multiplet peak patterns of 13C glutamate C2, C4, C3 glutamate resonances. c Metabolomic profile—metabolite fold change
normalized to control concentration (PLMWT levels= 1) with propagated errors (SEM). 1H NMR metabolomic analysis: NAD, ATP+ADP, PCr, creatine,
carnitine, phosphocholine, choline, acetyl carnitine, acetate, aspartate, glutamine, glutamate, glycine, alanine. GS-MS/MS analysis: pyruvate, lactate,
citrate, isocitrate, α-ketoglutarate, succinate, fumarate, malate (PLM3SA n= 5, PLMWT n= 8; lactate PLM3SA n= 12, PLMWT n= 10, succinate, glutamate
PLM3SA n= 14 PLMWT n= 10, aspartate PLM3SA n= 13 PLMWT n= 10) (*P < 0.05 vs PLMWT, succinate, citrate, glutamine, alanine P < 0.005 vs PLMWT
by t-test, two tailed, df= 10). d Representative 1H metabolomic NMR spectra. e Myocardial energetic reserve (PCr/ATP) ratio determined by 31P NMR
spectroscopy (PLM3SA n= 14, PLMWT n= 7, P < 0.22, vs control by t-test, two tailed, t= 1.2, df= 19). f Representative 31P spectra of PLMWT and PLM3SA
hearts. g Impact of 30min perfusion with 1μM CGP37157 in KHmetab buffer on 1H NMR metabolomic profile of PLM3SA versus PLMWT hearts. Metabolite
fold change vs control (control= 1) with propagated error of mean. (n= 8/group PLM3SA and PLMWT). **P < 0.05 vs PLMWT,succinate, citrate, glutamine,
alanine P < 0.005 vs PLMWT by t-test, two tailed, df= 10. Data are mean ± SEM. Source data are provided as a Source Data file.
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details). Our experimental data show that while Na elevation re-
programs metabolism, it does so while not compromising ener-
getics—as demonstrated by our 31P-NMR measurements show-
ing maintained ATP, PCr, PCr/ATP ratios and pHi. Therefore, we
defined the optimisation problem to maximize ATP provision
within a set of constraints defined by our experimental condi-
tions. We included experimentally measured metabolic data
during acute and chronic Nai elevation into the simulations to
determine which metabolic pathways are consistent with the
cardiac adaptation during our experimental conditions. These
simulations were conducted without constraining enzymatic
activities; thus the optimisation problem was defined by experi-
mentally determined metabolite levels. Our modelling did not
include Ca-dependence as a variable, because electrolytes are
not part of the Cardionet metabolic network. Principal compo-
nent analysis (PCA) (Supplementary Fig. 7) of estimated flux
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distributions clearly classified samples according to their Nai
elevation status. Unsupervised hierarchical cluster analysis
(Fig. 5) together with annotation enrichment of the observed
clusters (Supplementary Fig. 8) showed that Nai elevation affected
a multitude of metabolic pathways, and therefore defined a pos-
sible metabolic hallmark of Nai elevation irrespective of its
duration or aetiology. Key reactions involved in glycolysis, Krebs
cycle and OXPHOS reactions were upregulated (P < 0.05; Fig. 5).
Likewise modelling estimated an enhanced amino acid, phos-
pholipid and purine metabolism while predicting a reduction in
the metabolism of fatty acids, ketone bodies and nucleotides
(Fig. 6). Interestingly, in acute Nai overload, the model identified
that a reduction in fatty acid utilisation created extensive need for
enhanced metabolism of pyruvate, lactate and amino acids to
maintain normal Krebs cycle and oxidative phosphorylation flux.
In chronic Nai overload, the model identified that reduction of
fatty acid oxidation enhanced glucose utilisation and ketone
metabolism leading to increased fluxes through the Krebs cycle
(including CaDHmito) and oxidative phosphorylation (Fig. 6).
Together our in silico modelling showed that elevation of Nai
promotes a shift from fatty acid towards glucose oxidation and
extensive metabolic flux remodelling resulting in maintained ATP
synthesis. We validated our model by comparing the experi-
mentally determined metabolic profile to our simulations.
Mathematically predicted metabolite changes correlate with
experimentally determined changes (R2= 0.72; Pearson correla-
tion coefficient, r= 0.85; Supplementary Fig. 9). We conclude
that our mathematical simulations recapitulated the experimen-
tally observed metabolic profile—in particular regarding the shift
from fatty acid ß-oxidation towards carbohydrate oxidation—
while expanding our understanding of cardiac metabolic adap-
tation in response to Nai elevation.
Discussion
We hypothesised that elevated myocardial Nai may be a unifying
mechanism leading to myocardial metabolic remodelling
regardless of its aetiology (pharmacological, transgenic or
pathological hypertrophy–mediated Na/K ATPase inhibition) or
duration (acute-30 min, chronic-5 or 25 week Nai overload) that
precedes the onset of energetic deficit and functional deteriora-
tion. We used an experimental approach combining retrogradely
perfused mouse hearts under physiological conditions (tempera-
ture, O2 availability, pH, unrestricted metabolic substrate avail-
ability) with continuous non-invasive NMR (23Na and 31P),
Fig. 2 Metabolic profile of pressure-overload induced (banding) hypertrophy. a representative Sham control and banded hypertrophy (dry hearts).
b Myocardial 13C MRS assessment of oxidative metabolism—% contribution of 13C-U palmitate, 13C 1,6 glucose and the remnant unlabelled 12C substrate
pool (triglycerides, glycogen, pyruvate, lactate, ketone bodies). Impact of the mitochondrial Na/Ca exchange inhibition with CGP37157 on metabolic fluxes:
myocardial 13C NMR assessment of oxidative metabolism after 30min administration of CGP37157 in 13C-KHmetab buffer—% contribution of 13C-U
palmitate, 13C 1,6 glucose and the remnant unlabelled 12C substrate pool to oxidative phosphorylation Banded vs Sham hearts (n= 5/group). Banded vs
Sham palmitate oxidation P < 0.05, glucose oxidation P < 0.005, unlabelled P < 0.03 by t-test (two-tailed); Banded+ CGP37157 vs banded P < 0.05, by
one-way ANOVA and Bonferroni multiple comparisons post-test. c 1H NMR metabolite profile - fold change normalized to control concentration (Sham
levels= 1) with propagated error (SEM) (n= 6/group). *P < 0.05 vs control by t-test (two tailed, df= 9). d Impact of 30min perfusion with 1 μM
CGP37157 in KHmetab buffer on 1H NMR metabolomic profile of Banded (n= 4) versus Sham (n= 5) hearts. *P < 0.05 vs Sham, by t-test (two tailed) ♯♯P <
0.01 PCr vs. Sham+ CGP37157, P < 0.01 Aspartate Banded CGP37157 vs Sham by one-way ANOVA and Bonferroni multiple comparisons post-test. Data
are mean ± SEM. Source data are provided as a Source Data file.
60a
Treatment
Treatment
Ouab
Ouab + Blebbi
Control
40
20
0
0 20
Time (min)
40 60 0 20
Time (min)
40 60
0 20
Time (min)
40 600 20
Time (min)
40 60
N
a i
 (
m
M
)
300
6
4
2
0
200
100
0
LV
D
P
 (
m
m
H
g)
C
or
on
ar
y 
flo
w
 (
m
l/m
in
)600
400
200
0
H
ea
rt
 r
at
e 
(b
pm
)
Blebbi
Ouab
Ouab + Blebbi
Control
Blebbi
Ouab
Ouab + Blebbi
Control
Blebbi
Treatment
Treatment
Ouab
Ouab + Blebbi
Control
Blebbi
b
c d
Fig. 3 Impact of acute 30min Na/K ATPase inhibition on Nai and ex vivo function. a Time course of Nai elevation measured by 23Na TQF filtered NMR.
40min P < 0.01 vs baseline, 45 and 50min P < 0.0001 vs baseline. b Impact on left ventricular developed pressure (LVDP) **P < 0.01 versus baseline.
c Heart rate (HR) and d coronary flow. Data are presented as mean ± SEM. Ouab= 75 μmol/l ouabain (n= 8); Ouab+ Blebbi= 75 μmol/l ouabain+ 100
nmol/l blebbistatin (n= 11); Control= KH buffer+ vehicle (DMSO) (n= 7); Blebbi= 100 nmol/l blebbistatin (n= 5). P value is for the effect of the drug
treatment by two-way ANOVA. Source data are provided as a Source Data file.
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steady-state 13C NMR analysis of substrate utilization and flux,
high-resolution 1H NMR metabolic profiling, traditional in vitro
biochemical methods (LC GC MS/MS) as well as in silico com-
puter modelling to assess the impact of regulating Nai (via Na/K
ATPase inhibition) on mitochondrial ATP provision.
Chronic cardiac Nai elevation in the PLM3SA mouse was
associated with adaptations in cardiac metabolism with a switch
in substrate preference from oxidation of fatty acids to carbo-
hydrates (glucose)23. This switch appears to be adaptive in the
chronic situation as high-energy phosphate and redox metabolite
pools (PCr/ATP, NADH) are maintained. However, our results
suggest that in the long term, metabolic remodelling in response
to chronically elevated Nai may be insufficient to compensate,
indicated by a sustained depletion of metabolic substrates such as
lactate and amino acids24,25 and reduced intracellular lipid
metabolism compared to WT mice. Na/Camito inhibition by
CGP37157 normalized the substrate utilisation profile (palmitate
oxidation) as well as normalising the levels of depleted metabo-
lites in PLM3SA hearts with chronically elevated Nai.
Our study shows that Na-elevation does not compromise
energy supply as evidenced by conserved concentration of ATP
and PCr, as well as, ATP/PCr ratios. In concordance with our
experimental studies, mathematical modelling using CardioNet
predicted remodelling of cardiac metabolism during chronic Nai
elevation, maintenance of normal ATP provision through
increased glucose oxidation and anaplerotic replenishment of
Krebs cycle flux. It shows that the impact of impaired Nai
homeostasis on mitochondrial ATP production is mechanistically
more complex than previous studies suggested using isolated cells
and organelles and that there is no evidence of an energetic
deficit.
When cytoplasmic Na was chronically elevated, Na/Camito
inhibition by CGP37157 normalised the altered substrate utili-
zation profile (palmitate oxidation) and normalising the levels of
depleted anaplerotic metabolites in PLM3SA hearts. However,
when CGP37157 was administered to control hearts (in the
absence of chronic Na elevation) it had only a negligible effect on
cardiac metabolism (Figs. 1 and 2) and function (Online Sup-
plement Fig. 6). While there is a wealth of literature (including in
the heart) showing that CGP37157 inhibits NCLX when the
system is perturbed, when matrix Ca is measured using mito-
chondrially targeted aequorin, CGP37157 does not increase basal
matrix Ca26. This suggests that lowering NCLX activity below
basal conditions does not do the opposite to increasing the
100
4
3
2
1
0
NA
DH
AT
P 
+ 
AD
P
PC
r
Cr
ea
tin
e
La
cta
te
Ci
tra
te
Iso
cit
ra
te
α-
ke
to
glu
ta
ra
te
Su
cc
ina
te
Fu
m
ar
at
e
M
ala
te
Ca
rn
itin
e
Ch
oli
ne
Ac
et
at
e
As
pa
rta
te
Gl
ut
am
ine
Gl
ut
am
at
e
Ac
et
yl 
ca
rn
itin
e
Ph
os
ph
oc
ho
lin
e
Py
ru
va
te
80
60
%
 C
on
tr
ib
ut
io
n 
to
 o
xi
da
tiv
e 
m
et
ab
ol
is
m
F
ol
d 
ch
an
ge
 (
O
ua
b 
+
 B
le
bb
i v
s 
C
on
tr
ol
)
F
ol
d 
ch
an
ge
 (
vs
 C
on
tr
ol
)
40
20
4
3
2
1
0
Lactate Citrate Succinate Fumarate Malate
3
2
P
C
r/
AT
P
 (
A
.U
.)
1
0
0
13C Palmitate 13C Glucose 13C Glucose + Unlabelled
Ouab blebbi
Ouabain blebbi
CGP 37157 Ouabain blebbi
CGP 37157
Control
Energetics and redox
Glycolysis
TCA cycle
Lipid metabolism
Amino acid metabolism
Gl
yc
ine
Al
an
ine
Ouab Ouab + BlebbiControl Blebbi
a b
c d
Fig. 4 Impact of acute 30min Nai elevation on myocardial metabolism. a Myocardial 13C NMR assessment of oxidative metabolism—% contribution of
13C-U palmitate, 13C 1,6 glucose and the remnant unlabelled 13C substrate pool (pyruvate, lactate, amino acids, triglycerides, glycogen). 13C glucose+
unlabelled= 100%-13C palmitate oxidation) (n= 5/group) ***P < 0.005 vs control by unpaired t-test (two-tailed, t= 3.74 df= 8). b Metabolic profile
plotted as metabolite fold change normalized to control concentration (control levels= 1) with propagated error (SEM). 1H NMR metabolite analysis: NAD,
ATP+ADP, PCr, creatine, carnitine, phosphocholine, choline, acetyl carnitine, acetate, aspartate, glutamine, glutamate, glycine, alanine. GC and LC-MS/
MS analysis: pyruvate, lactate, citrate, isocitrate, α ketoglutarate, succinate, fumarate, malate. C57/BL6 hearts perfused for 30min with Control= Krebs
Henseleit buffer+ vehicle (DMSO); Ouab= 75 μmol/l ouabain; Blebbi= 100 nmol/l blebbistatin; Ouab+ Blebbi= 75 μmol/l ouabain+ 100 nmol/l
ouabain. P < 0.005 vs control by unpaired t-test (two-tailed, df= 2.2). c Energetic reserve PCr/ATP (Control n= 8, n= 4/treatment group, *P < 0.001 vs
control by one-way ANOVA F= 8.6). d Impact of the mitochondrial Na/Ca exchange inhibition with CGP37157 on GC-MS/MS metabolic profile.
CGP37157+Ouab+ Blebbi= 1 μmol/l CGP37157+ 75 μmol/l ouabain+ 100 nmol/l blebbistatin; CGP37157= 1 μmol/l CGP37157; Control= KH
buffer+ vehicle (DMSO); Blebbi= 100 nmol/l blebbistatin (n= 5/group)*P < 0.05 lactate, P < 0.0002 citrate, succinate, fumarate, malate vs control by
one-way ANOVA. Data are mean ± SEM (a, c) and fold change versus control (control= 1) with propagated error of mean (b, d). Comparisons by one-way
ANOVA were subject to Bonferroni multiple comparisons post-test. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18160-x ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4337 | https://doi.org/10.1038/s41467-020-18160-x | www.nature.com/naturecommunications 7
Malonyl-CoAdecarboxylase1 Transaldolase
Phosphoglyceratemutase
Phosphoglyceratekinase
Glyceratekinase
Glyoxylatereductase
6-phosphogluconolactonase1
Glucose-6-phosphate1-dehydrogenase1
UTP--glucose-1-phosphateuridylyltransferase
UDP-sugardiphosphatase
Phosphoglucomutase
Bisphosphoglycerate mutase
Bisphosphoglyceratemutase
Hexokinase
Enolase
Glyceraldehyde3-phosphatedehydrogenase
6-phosphogluconolactonase2
Glucose-6-phosphate1-dehydrogenase2
Triosephosphateisomerase
Isocitrate dehydrogenase
Isocitratedehydrogenase(NAD+)
CR00192_mito
CR00179_mito
CR01295_mito
Aconitatehydratase
Fumaratehydratase2
Fumaratehydratase1
Citratesynthase
Citratelyase
Ba
se
line
Ac
ute
 Na
 el
eva
tio
n
Ch
ron
ic N
a e
lev
ati
on
Ba
se
line
Ac
ute
 Na
 el
eva
tio
n
Ch
ron
ic N
a e
lev
ati
on
2-oxoglutaratedehydrogenase
ATPcitratelyase
Malatedehydrogenase2
Malatedehydrogenase3
Malatedehydrogenase4
Malatedehydrogenase1
Pyruvatedehydrogenase
Pyruvatecarboxylase
Pyruvate kinase
Phosphoenolpyruvatecarboxykinase
D-3-phosphoglyceratedehydrogenase
Alphaketoglutaratedehydrogenase
Succinyl-CoAsynthetase
Adenylosuccinatelyase
Succinate-semialdehydedehydrogenase(NADP+)
Succinate-semialdehydedehydrogenase
Malonyl-CoAdecarboxylase2
Krebs cycle and OXPHOS Glucose metabolism
z-score
1
0.5
0
–0.5
–1
Fig. 5 Metabolic adaptation in response to acute and chronic Na elevation. Unsupervised hierarchical clustering of estimated z-scored flux rate changes
reveals metabolic adaptation in response to [Na]i elevation. Heat maps summarize results for reactions in the Krebs cycle, OXPHOS, and glucose
metabolism. Flux distributions were calculated by Flux balance analysis (FBA) using the mammalian network of cardiac metabolism, CardioNet. Z-scores
were calculated to visualize how many standard deviations an estimated flux rate is away from the mean across all experimental groups. The z-score
describes the distance from the mean for a given flux rate as a function of the standard deviation. For example, a z-score equal to 1 represents a flux for a
given experimental group that is 1 standard deviation greater than the mean across all experimental groups. The colour scale indicates the degree to which
estimated flux rate changes are predicted to be respectively lower or higher in response to Nai elevation. Source data are provided in Supplementary Data 1.
2PG_cyto
1,3DPG_cyto
PEP_cyto
3PG_cyto
Fructose-6P_cyto
Erythrose-4P_cyto
AMP_cyto
3-Phosphonooxypyruvate_cyto
Adenosine_cyto
ADP_cyto
NAD+_cyto
Glucono-1,5-lactone-6P_cyto
Ribulose-5P_cyto
NADPH_cyto
6-Phospho-D-gluconate_cyto
Ribose-5P_cyto
D-Xylulose-5P_cyto
Ribose-1P_cyto
Sedoheptulose-7P_cyto
NADH_cyto
GAP_cyto
DHAP_cyto
Fructose-1,6PP_cyto
Glucose_cyto
Glucose-6P_cyto
NADP+_cyto
O2_cytocis-Aconitate_mito
NADPH_mito O2_ext
Fumarate_mito
Succinate_mito
OAA_mito
Malate_mito
CoA_cyto
L-Lactate_mito
L-Lactate_cyto
Pyruvate_cyto
Pyruvate_mito
ATP_cyto
Glycogenin-G7G1_cyto
Glycogenin-G4G7_cyto
Glucose-1P_cyto
Glycogenin_cyto
Glycogenin-G7_cyto
Glycogenin-G4G4_cyto
Succinyl-CoA_mito
ADP_mito
NADH_mito
FADH2_mito
NAD+_mito
Glucose_ext
Citrate_mito
L-Lactate_ext
Acetate_cyto
Acetoacetyl-CoA_mito
Acetate_mito
Glutamate_mito
Oxalosuccinate_mito
Aspartate_mito
Isocitrate_mito
Acetyl-CoA_mito
NADP+_mito
CoA_mito
AKG_mito
O2_mito
FAD_mito
Palmitoyl-CoA_mito
ATP_mito O2_mito
Oxalosuccinate_mito
Glutamate_mito
Aspartate_mito
Isocitrate_mito
Malate_mito NADP+_mitoNADH_mito
NAD+_mito
NADPH_mito
OAA_mito Citrate_mito
L-Lactate_cyto
L-Lactate_ext
cis-Aconitate_mito O2_cyto
O2_ext
Fumarate_mito
Succinate_mito
CoA_cyto FAD_mito
ATP_mito
Pyruvate_mito Acetoacetyl-CoA_mito
Acetate_cyto
L-Lactate_mito
Acetyl-CoA_mito
Acetate_mito
FADH2_mitoADP_mitoCoA_mito
Palmitoyl-CoA_mito
Succinyl-CoA_mitoAKG_mito
3-Phosphonooxypyruvate_cyto
AMP_cytoADP_cyto
Adenosine_cyto
NADH_cyto
ATP_cyto
NAD+_cyto
DHAP_cyto
GAP_cyto
1,3DPG_cyto
Fructose-1,6PP_cyto
3PG_cyto
Fructose-6P_cyto
Erythrose-4P_cyto
Glucose-6P_cyto
Glucose_cyto
Glucose_ext
Glycogenin_cyto
Glucose-1P_cyto
Glycogenin-G4G7_cyto
Glycogenin-G7G1_cyto
Glycogenin-G7_cyto
Glycogenin-G4G4_cytoPEP_cyto
Pyruvate_cyto
2PG_cyto
Ribulose-5P_cyto
NADP+_cyto
Glucono-1,5-lactone-6P_cyto
NADPH_cyto
6-Phospho-D-gluconate_cyto
Ribose-1P_cyto
Ribose-5P_cyto
D-Xylulose-5P_cyto
Sedoheptulose-7P_cyto
Acute Na elevation Chronic Na elevation
Fig. 6 CardioNet in silico metabolic flux changes in response to acute and chronic Nai elevation. Graph denotes estimated flux distribution in response to
acute and chronic Nai elevation. The coloured nodes represent metabolites assigned to five different compartments: extracellular space, cytosol,
mitochondria, microsome, lysosome. The black square nodes indicate reactions; two reactions are linked by a directed edge indicating the reaction flux. The
line thickness of each edge is proportional to predicted flux rate change. Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18160-x
8 NATURE COMMUNICATIONS |         (2020) 11:4337 | https://doi.org/10.1038/s41467-020-18160-x | www.nature.com/naturecommunications
activity under Na-loaded conditions perhaps due to a non-linear
relationship between NCLX and intra-mitochondrial Ca.
Pressure-overload induced hypertrophy by aortic banding
resulted in significant hypertrophy, in vivo dysfunction and
myocardial Nai overload after five weeks. 13C assessment of
oxidative substrate utilization in hypertrophied perfused hearts
revealed a substrate switch from palmitate to glucose oxidation in
keeping with the literature and of similar magnitude to that
observed in the chronic Na elevation in PLM3SA hearts16,27.
Similarly to PLM3SA, there was no evidence of energetic
impairment or increase in anaerobic glycolysis. However, a gen-
eral decline in energy substrate metabolism is not a uniform
finding in all hypertrophy and heart failure models19 including
ours, highlighting involvement of alternative metabolic aetiolo-
gies. Our study revealed that metabolic remodelling occurs during
chronic hypertrophy induced Nai overload independent of
structural and functional remodelling, and this remodelling
causes a substrate switch favouring utilization of glucose over
fatty acids. Na/Camito inhibition by CGP37157 normalized the
substrate utilization profile (reversal to palmitate as the main
oxidative fuel) in hypertrophic hearts. Collectively, these obser-
vations suggest that the early prevention of myocardial Nai ele-
vation (and consequent decline in mitochondrial matrix Ca) has
the potential to reverse metabolic derangement in pathological
hypertrophy by preventing deterioration in energy substrate uti-
lization, oxidative phosphorylation and high-energy phosphate
transfer.
Acute Nai elevation via pharmacologic Na/K ATPase inhibition
with ouabain, in the presence of blebbistatin, resulted in increased
Nai combined with the most severe metabolic remodelling
observed in our study: depletion of Krebs cycle intermediates
including citrate, succinate, fumarate, malate and a substrate
switch from fatty acid oxidation to increased use of other fuels,
primarily carbohydrates (pyruvate, lactate). There was no com-
promise in levels of high-energy phosphates nor in the redox
state. No changes in coronary flow, PCr/ATP ratio nor succinate
tissue levels were observed, indicating that acute Nai elevation
does not cause ischaemia nor energetic compromise. Experi-
mental findings were consistent with computational estimation of
the metabolic changes using CardioNet21. With the contribution
of fatty acid β-oxidation to ATP provision decreased, simulations
showed that ATP provision for contractile work is maintained
due to compensatory increase of amino acid and carbohydrate
utilisation (pyruvate, lactate) to replenish Krebs cycle inter-
mediates. Maintained contractile function and ATP provision in
the face of high Nai comes at the cost of increased metabolic
substrate utilization and enhanced fluxes leading to significant
metabolite depletion. These findings are in keeping with pre-
viously reported features of metabolic inefficiency arising from
simultaneously increased yet mismatched metabolic fluxes and a
failure of fatty acid β-oxidation to compensate28,29. Administra-
tion of the Na/Camito exchanger antagonist CGP37157 in acute
Nai overload completely abrogated the metabolic changes
(intracellular metabolite levels and Krebs cycle intermediate
concentrations) highlighting the importance of cytosolic Nai in
regulating mitochondrial matrix Ca. However, our data show that
in the perfused beating heart acute Nai elevation resulted neither
in decreased oxidative metabolic flux nor ATP and NADH
depletion, thus the impact of impaired Nai homeostasis on
mitochondrial ATP production is mechanistically more complex
than previous studies suggested using isolated cells and
organelles30,31.
Historically, CGP37157 with its submicromolar inhibitory
potency (IC50 0.4 µM) has been suggested as a candidate for the
augmentation of ATP reserves in heart failure, insulin-dependent
diabetes mellitus and acute myocardial infarction via Na/Camito
inhibitory mechanism32,33. In vivo studies utilizing chronic
CGP37157 delivery in a guinea pig model of sudden cardiac death
and heart failure suggested anti-arrhythmic potential of the
drug34. However, in separate cohort studies concerns were raised
regarding the inhibitory effect on insulin secretion35,36 as non-
specific effects on microsomal Ca flux (ryanodine receptor/
SERCA) and other Ca channels and transporters in myocytes35,37.
Therefore, further characterization of CGP37157 or more selec-
tive Na/Camito inhibitors would be required before considering
this approach to the treatment of Nai induced-metabolic remo-
delling in cardiac pathologies.
How much of CGP37157 actually reaches the mitochondria
and how that translates into Na/Camito inhibition is unknown due
to a lack of direct way to measure Na/Camito inhibition in an
intact heart. Given the lethality of the Na/Camito KO38, complete
inhibition of NCLX may be catastrophically detrimental. How-
ever, in our studies it seems that partial, transient inhibition is
survivable in the short term. It is clear, however, that even if the
NCLX inhibition is partial, it is sufficient to acutely prevent the
metabolic switch. Given CGP37157 would treat a secondary effect
of elevated Nai rather than a primary cause, our study suggests
that in order to ameliorate metabolic dysfunction in pathological
hypertrophy, pharmacological activation of Na/K ATPase to
address Nai overload may be a superior therapeutic strategy with
fewer side effects2,12. The outcome of our study also highlights
the likely unsuitability of cardiac glycosides (digoxin) for the
treatment of hypertrophy and heart failure as they elevate Nai and
would thus cause rather than prevent metabolic remodelling.
This study shows that cytoplasmic Na elevation, irrespective of
its aetiology or duration, is instrumental in driving metabolic
changes, including substantive reprogramming of substrate
metabolism, without compromising energetics. These changes are
blocked by an inhibitor of mitochondrial Na/Ca exchange sug-
gesting that this reprogramming involves Na-dependent changes
in mitochondrial matrix Ca as the end effector. In the present
study, mitochondrial matrix Ca was not measured nor have key
Ca-sensitive enzymes been identified, thus the exact nature of
such interactions remain to be determined.
A feature of this reprogramming is that it does not appear to
compromise energy supply as ATP, PCr and ATP/PCr ratios are
conserved. Our study-design investigating acute ouabain expo-
sure attempts to keep ATP demand constant by using blebbistatin
titration to limit the induced inotropy. However, while in the
beating myocardium, myosin ATPase is responsible for the vast
majority of ATP consumption (76%), SERCA and Na/K ATPase
also contribute (15% and 9% respectively)39. In the present
experiments, energy consumption through these pathways may
therefore slightly increase but this does not appear to reach the
level where ATP supply and energetics are compromised.
Lastly, mathematical modelling of complex biological systems
is biased towards known enzymes and metabolites. CardioNet
does not include simulations of electrolyte sensitivities and con-
sequently CardioNet cannot identify specific Ca or Na-sensitive
enzymes or model their response to ionic changes. Nevertheless,
the model does allow pathways to be identified at a systems-wide
level that are altered in response to acute and chronic Na eleva-
tion based on measured experimental metabolic profiles.
Myocardial Nai overload leads to a complex series of metabolic
perturbations including a switch in substrate reliance from fatty
acid oxidation to increased reliance on carbohydrates for ATP
provision, with a predicted alteration in mitochondrial metabolic
fluxes at the expense of metabolic coupling and a resulting
depletion of metabolite pools. These changes appear to be inde-
pendent of the cause of Nai elevation, duration of the Na/K
ATPase inhibition or pathological origin. The metabolic altera-
tions precede energetic and functional impairment in the heart
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thus preventing a Nai induced mismatch between ATP supply
and demand. Alterations in Na/Camito exchanger activity by
cytosolic Nai overload contribute to the observed metabolic
changes as treatment with the antagonist CGP37157 ameliorates
the metabolic adaptations observed. The dynamics of metabolic
remodelling due to altered Nai occur before structural and
functional remodelling of the failing heart. Whether these adap-
tations become maladaptive under stress warrants further
investigation.
Methods
Animals. Hearts were isolated from male C57BL/6J male mice (~20–25 g) (Charles
River JAXTM stock number 000664) or from WT and PLM3SA knock-in mice18.
This investigation complied with all the relevant ethical regulations for animal
testing and research: UK Home Office Guidance on the Operation of the Animals
(Scientific Procedures) Act, 1986.
PLM3SA knock-in mice were backcrossed with C57BL/6J mice (Charles River,
UK) for >5 generations and were generated by heterozygous pair mating. The
PLM3SA mouse expresses a non-phosphorylatable form of PLM in which Ser 63,
68, and 69 have been mutated to alanine and exhibits a Na/K ATPase that is
unresponsive to kinase regulation and hence shows chronically elevated Nai15.
Unless otherwise stated, littermates were used as the appropriate wild-type controls
(PLMWT). Animals were kept under pathogen-free conditions, 12-h light–dark
cycle, controlled humidity (~40%), temperature (20–22 °C), and fed chow and
water ad libitum. All animals used in studies were male. For pharmacologically
induced acute Nai elevation studies, 6-week-old C57BL/6J male mice (~25 g body
weight) were purchased from Charles River (UK). Myocardial hypertrophy was
induced in 6-week-old C57BL/6J mice (20–22 g) (Charles River, UK). For cellular
compartmentation of the 23Na TQF NMR signal experiment, Male Wistar rats
(250 g) were purchased from Charles River, UK.
Glucose tolerance test. Oral glucose tolerance test40 was performed after 5 h fast
(n= 8/group), (50 mg glucose, oral gavage).
Tissue and plasma collection. After an overnight fast, blood was collected from
vena cava from terminally anaesthetized mice (PLM3SA and PLMWT) by hepar-
inized 1 ml syringe and immediately centrifuged in pre-cooled vials (3000 rpm, 4 °
C, 10 min) to obtain plasma. Skeletal muscles (gastrocnemius and soleus) were
dissected and snap frozen by Wollenberger tongs for 1H NMR metabolic profiling.
Concentrations of adiponectin, alanine aminotransferase, alkaline phosphatase,
creatine kinase, free fatty acids, glucose, high density lipoprotein, insulin, lactate,
lactate dehydrogenase, triacylglycerols, adrenaline and noradrenaline were mea-
sured by the Mouse Biochemistry Laboratory, Addenbrooke’s Hospital, Cambridge
University Hospitals NHS Trust. In a separate cohort of non-fasted terminally
anaesthetized animals (n= 5/group), the heart, and skeletal muscle (mixed soleus
and gastrocnemius) were excised, snap frozen in liquid nitrogen and stored at −80
°C for 1H NMR metabolomic profiling, western blotting assessment of protein
expression and messenger RNA qRT- PCR. RNA was isolated using RNeasy
Fibrous Tissue Kit (Qiagen) according to the manufacturer’s instructions. RNA
quantity and quality was assessed using Nanodrop (ThermoFisher) and only RNA
with 260/280 > 1.8 was used for downstream analyses.
500 ng total RNA was reverse transcribed using Superscript VILO cDNA
synthesis kit (ThermoFisher). For quantitative PCR, gene specific primer sequences
(Supplementary Table 1: glut1, glut4, cd36, caspase 3, pdk 4, ucp3, cpt1, atg3, mte-1)
were obtained from PrimerBank (https://pga.mgh.harvard.edu/primerbank/).
PCR specificity and efficiency were confirmed for each primer pair prior to use.
2.5 ng of cDNA was used per qPCR reaction in triplicates using Power SYBR Green
PCR Master Mix (ThermoFisher) according to the manufacturer’s instructions
with the following cycling conditions: 95 C for 10 min, 40 cycles of 95 C for 15 s
and 60 C for 1 min using AB 7900HT (Applied Biosystems) qPCR cycler (SDS
software v 2.4).
The relative quantity of each gene was calculated using ΔΔCT method with
gapdh as endogenous control. Myocardial protein expression of IDH3 and pyruvate
dehydrogenase (PDH) was examined using manufacturer supplied methods for
extraction and detection (Abcam). The following antibodies were for the western
blotting experiments: rabbit-anti-IDH3A, Abcam,ab58641 (1.25 μg ml−1), anti-
rabbit, GE Healthcare NA934V (1:5000 dilution), rabbit -anti-α/β Tubulin, Cell
Signalling, 2148-S / 7 (1:2000), anti-rabbit, GE Healthcare,NA934V (1:2000
dilution), mouse-anti-PDH, Abcam, ab110333 (1 μg ml−1),anti-mouse, GE
Healthcare, NA931V (1:2000 dilution). Blots were scanned and analysed using
Biorad Gel 800 scanner and Image Lab software (v 6.1).
Cardiac hypertrophy. Myocardial hypertrophy was induced by pressure overload
following supra-renal aortic constriction (banding) in 6-week-old C57BL/6J mice
(20–22 g)18. Cardiac function and morphometry was measured in vivo in anaes-
thetized mice 5-weeks post-surgery using 2D echocardiography (Visualsonics
Vevo 770).
Langendorff-heart perfusions. Mice were terminally anesthetized, hearts
rapidly excised, cannulated and perfused as a standard Langendorff preparation41
or using a custom-built NMR-compatible perfusion system in which hearts were
beating spontaneously17. Mice were terminally anesthetized using pentobarbitone
(~140mg kg−1 i.p.), hearts rapidly excised, cannulated and perfused as a standard
Langendorff preparation41 or using a custom-built NMR-compatible perfusion sys-
tem in which hearts were beating spontaneously17. To study substrate preference and
metabolic flux rates using 13C-labelled substrates, we adapted the standard perfusion
system to utilise a counter-current membrane oxygenator41. At the end of each
experiment, hearts were immediately freeze-clamped using Wollenberger tongs for
metabolic profiling by 1H NMR, 13C NMR and GC-, LC-MS/MS.
Blebbistatin and CGP 37157 Krebs-Henseleit (KH) buffer. Pilot studies were
performed in C57BL6/J perfused mouse hearts in order to determine the working
concentrations of pharamacological agents used in the study: Na/K ATPase inhibitor
ouabain (Sigma Aldrich,UK), myosin II inhibitor 1-phenyl-1,2,3,4-tetrahydro-4-
hydroxypyrrolo[2.3-b]-7-methylquinolin-4-one (blebbistatin, Sigma Aldrich, UK) and
mitochondrial Na/Ca exchanger inhibitor 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-
4,1-benzothiazepin-2(3H)-one (CGP13757, Sigma-Aldrich UK). In order to avoid
precipitation of the blebbistatin in the vasculature and resultant ischaemia, 3.42
mmol/l blebbistatin stock solution (DMSO-diluted, aliquoted, frozen) was dissolved in
KH buffer according to the previously described protocol42. To eliminate the possi-
bility that any direct interaction between blebbistatin (DMSO) and ouabain mixed
together in aqueous solution leads to the production of new chemical entities or
binding between the two drugs, buffer samples [5 µmol/l blebbistatin (0.029% v/v
DMSO), 50 µmol/l ouabain and 5 µmol/l blebbistatin (0.029% v/v DMSO)+ 50 µmol/
l ouabain] were analysed by mass spectrometry (Agilent 1200 LC and Agilent 6510 Q-
TOF). No new chemical entities (peaks) were formed by mixing of the two phar-
macological agents, thus blebbistatin did not sequester ouabain in KH. Furthermore,
there was no impact of the added blebbistatin on the KH [Na+], [K+] and [Ca2+] as
analysed by Vetscan i-STAT1 analyser (CG8+ cartridge, Abaxis, UK).
Administration of ouabain causes immediate Na/K ATPase inhibition resulting
in immediate rise in Nai accompanied by positive inotropy. The final concentration
of ouabain (75 μmol l−1) chosen for the acute Nai elevation study protocols caused
significant Nai elevation which, when combined with 100 nM blebbistatin
eliminated ouabain-induced inotropy (Fig. 3b).
CGP13757 was re-suspended in DMSO (1 mg/ml), aliquoted and stored at 4 °C.
Final concentration used in KH (1 μmol/l) and the duration of administration was
based on previously published protocols in mitochondria, cells and perfused
hearts32–34. KH buffers containing pharmacological agents were prepared in amber
glassware immediately prior to the experiment.
Metabolic KH buffer and perfusion protocols. For the assessment of the relative
contributions of exogenous metabolic substrates (glucose and palmitate) to myo-
cardial oxidative metabolism (n= 7/group) substrate-enriched metabolic KH
Buffer (KHmetab) was used. In KHmetab the glucose concentration was 5 mmol l−1
and the following additional substrates and compounds included (in mmol/l):
1 sodium L-lactate; 0.1 sodium pyruvate; 0.5 L-glutamic acid monosodium salt
monohydrate; 5 mU l−1 insulin (NovoRapid insulin, Novo Nordisk, Denmark) and
0.3 sodium palmitate with 3% (w/v) bovine serum albumin (BSA, Proliant Biolo-
gicals, USA)43. Prior to inclusion, BSA was dissolved and purified as previously
described43. KHmetab of identical composition (in terms of components and their
concentrations) but containing [U-13C] palmitate and [1,6-13C] glucose (Cam-
bridge Isotopes, Goss Scientific, UK) was used for 13C NMR substrate selection/
metabolic flux assessment (13C-KHmetab).
After a 20-min functional equilibration period with KH, hearts were randomly
assigned to treatment groups for perfusion:
C57BL6/J hearts.
(i) KH buffer plus vehicle (0.029% v/v DMSO).
(ii) KH buffer plus 75 μM ouabain.
(iii) KH buffer plus 100 nM blebbistatin.
(iv) KH buffer plus 75 μM ouabain and 100 nM blebbistatin.
(v) KH buffer plus 1 μM CGP13757.
(vi) KH buffer plus 1 μM CGP13757, 75 μM ouabain and 100 nM blebbistatin.
(vii) Metabolic K-H plus 75 μM ouabain and 100 nM blebbistatin.
PLM3SA and PLMWT hearts.
i. KH buffer perfusion, paced at 550 beats min−1 via epicardial silver wire
electrodes placed at the apex of the left ventricle and the right atrium.
ii. KH buffer perfusion unpaced.
Banded and sham control hearts.
i. KH buffer perfusion.
ii. For 13C NMR substrate selection/metabolic flux analysis, PLM3SA, PLMWT,
banded and sham control hearts were functionally equilibrated for 30 min
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with KHmetab and switched to a 40 min perfusion with 13C-KHmetab.
Separate cohorts of PLM3SA, PLMWT, banded and sham control hearts after
equilibration were perfused for 40 min with 13C- KHmetab buffer with added
1 μmol l−1 CGP13757.
In situ 23Na and 31P NMR Langendorff perfusion protocols. All in situ NMR
Langendorff mouse heart perfusion experiments were carried out on a Bruker
Avance III 9.4 T 400MHz vertical wide-bore spectrometer (Bruker, Karlsruhe,
Germany) equipped with triple-axis gradients, a microimaging probe and
exchangeable RF coil inserts (10 mm 23Na coil or 10 mm 1H/31P dual tune coil).
Following cannulation on an MR-compatible umbilical perfusion rig, hearts were
perfused with phosphate free KH buffer (11 mM glucose) and subsequently low-
ered into the center of the magnet for real-time multiple quantum filtered 23Na
NMR (triple quantum filtered TQF and double quantum filtered DQF) quantifi-
cation of Nai and 31P NMR assessment of cardiac energetics as previously
described17,41. The hardware setup required changing between coils so that fully
relaxed 31P data were acquired at baseline prior to any elevation in Nai and at the
end of 30 min treatment protocol, while 23Na acquisitions were acquired
throughout the functional equilibration period and during the 30 min Nai eleva-
tion/drug treatment protocols. Fully relaxed 31P experiments were acquired with a
60° flip angle, 256 scans, a repetition time of 3.8 s and a total experiment duration
of 16 min. Nai quantification, the assessment of cardiac energetics and pH were
performed as previously described17,41. MQF 23Na experiments were acquired with
192 scans, 2048 data points, sweep width of 50 ppm, an acquisition time of 200 ms,
pre-scan delay of 200 ms and a total acquisition time of 1.24 min. The mixing time
(τm= 3.6 ms) was calibrated for the maximumTQF signal and set to be the same
for the DQF experiments. An exponential line broadening factor of 10 Hz was
applied prior to Fourier transformation and subsequent baseline correction. Peak
integrals were measured using Bruker Top Spin version 2.1 software.
The TQF Nai signal is a composite signal arising from the sum of various
compartments each with varying electrostatic interactions, Na concentrations, and
the volume occupied. The mechanism by which a TQF signal is produced is
through slow rotational reorientation of the Na ion giving rise to quadrupolar
relaxation when it is bound to macromolecules, and therefore largely from the
intracellular compartment although there is also a contribution from the
extracellular interstitial compartment. We have performed a series of in situ
multiple quantum filtered 23Na NMR spectroscopy experiments in order to assess
the cellular compartmentation of the 23Na TQF signal. In brief, this has involved
following the TQF signal while sequentially washing out
(i) the extracellular compartment (with a Na-free solution)
(ii) the cytosolic compartment (with a Na-free solution plus saponin). Saponin
should selectively permeabilise the cholesterol containing sarcolemma.
(iii) the mitochondrial compartment (with a Na-free solution plus Triton X-
100). Triton should permeabilise all other non-cholesterol-containing
membrane such as the mitochondria.
High resolution 1H NMR of tissue extracts. Frozen, weighed and pulverized
hearts were subject to methanol/ water/ chloroform dual phase extraction adapted
from Chung et al.44 The upper aqueous phase was separated from the chloroform
and protein fractions. 20–30 mg chelex-100 was added to chelate paramagnetic
ions, vortexed and centrifuged at 3600 RPM for 1 min at 4 °C. The supernatant was
then added to a fresh Falcon tube containing 10 µL universal pH indicator solution
followed by vortexing and lyophilisation. Dual-phase-extracted metabolites were
reconstituted in 600 µL deuterium oxide (containing 8 g L−1 NaCl, 0.2 g L−1 KCl,
1.15 g L−1 Na2HPO4, 0.2 g L−1 KH2PO4 and 0.0075% w/v trimethylsilyl propanoic
acid (TSP)) and adjusted to pH ≈ 6.5 using 1M hydrochloric acid and/or 1M
sodium hydroxide (<5 µL of each) prior to vortexing. The solution was transferred
to a 5 mm NMR tube (Norel Inc., USA) and then analysed using a Bruker Avance
III 400MHz (9.4 T) wide-bore spectrometer (Bruker, Germany) with a high-
resolution broadband spectroscopy probe at 298 K. A NOESY 1D pulse sequence
was used with 128 scans, 2 dummy scans, total repetition time 6.92 s, sweep width
of 14 ppm and an acquisition duration of 15 min. Data were analysed using
TopSpin software version 2.1 (Bruker, Germany), FIDs were multiplied by a line
broadening factor of 0.3 Hz and Fourier-transformed, phase and automatic
baseline-correction were applied. Chemical shifts were normalised by setting the
TSP signal to 0 ppm. Peaks of interest were initially integrated automatically using
a pre-written integration region text file and then manually adjusted where
required. Assignment of metabolites to their respective peaks was carried out based
on previously obtained in-house data, confirmed by chemical shift, NMR spectra of
standards acquired under the same conditions and confirmed using Chenomx
NMR Profiler Version 8.1 (Chenomx, Canada). Peak areas were normalized to the
TSP peaks and metabolite concentrations quantified per gram tissue wet
weight42,44. Intracellular concentration of NADH, ATP+ADP, phosphocreatine,
creatine, lactate, succinate, fumarate, carnitine, phosphocholine, choline, acetyl
carnitine, acetate, aspartate, glutamine, glycine, alanine was analysed. The fold
change with respect to the control group was then calculated for each metabolite.
LC-MS/MS. Lyophilised aqueous metabolite extracts were reconstituted in 350 µL
ultrapure water (Millipore Corporation, USA). A series of mixed standards were
prepared in ultrapure water containing 0.0025–50 µM of each metabolite. An
Agilent 1100 HPLC system (Agilent Technologies, USA) consisting of an auto-
sampler, a binary pump, a degasser unit and a column oven coupled to an Applied
Biosystems Sciex API 3000 mass spectrometer with Turbo Ionspray interface (MDS
Sciex, Canada). Chromatograpic separation was achieved using a Supelcogel C610-
H column (300 mm × 7.7 mm) with a Supelcogel H guard column (50 mm × 4.6
mm) (Supelco, USA) with an isocratic flow (0.4 mLmin−1) of mobile phase con-
sisting of 0.01% v/v formic acid and methanol (90:10) and an injection volume of
100 µL.
The HPLC eluate was split (4:1) just before the Turbo Ionspray interface
resulting in a flow of 0.1 mL/min into the mass spectrometer. In order to eliminate
peak to peak interference, two separate acquisitions were performed for each
sample and standard. Acquisition 1 included α-ketoglutarate (145 > 101m/z),
citrate (191 > 87m/z), isocitrate (191 > 155m/z), fumarate (115 > 71m/z) and
lactate (89 > 43m/z) whilst Acquisition 2 included pyruvate (87 > 43m/z), malate
(133 > 115m/z) and succinate (117 > 73m/z). Data were acquired using Analyst
software (version 1.4.2) and metabolite concentrations in the samples were
interpolated using calibration curves of each metabolite.
GC-MS/MS. Polar metabolites were extracted from the frozen pulverized cardiac
tissue (50 mg) using the modified Folch method involving methanol water and
chloroform with some modifications. Namely, a 200 µl of ice-cold distilled water
with 1 mcg Norvalin as internal standard was added to the samples and 1 h
sonication was performed in cold conditions. This was followed by addition of 500
µl HPLC grade methanol (ice cold) to each samples with 1 h sonication in ice cold
conditions. Subsequently, the methanol: water extract was transferred using glass
Pasteur pipette to a new labelled high grade Eppendorf tube and 500 µl chloroform
was added to each tube, vortexed for 1 min followed by 15 min shaking on the
shaker at high speed. Subsequently, the Eppendorf tubes were centrifuged at
13,000 rpm, 4 C for 15 min and the top polar layer was aspirated to a clean
Eppendorf tubes. The polar extract was dried using a speedvac and stored in −80
freezer for subsequent derivatization.
Derivatization method. All derivatization steps were carried out in a fume hood.
In order to derivatize proteinogenic amino acids, organic acids and glycolytic
intermediates for GC-MS analysis, the dried extract was incubated at 95 °C in open
tubes in order to remove any residual moisture in the samples. The dried extract
was solubilized in 40 μl of 2% methoxyamine HCL in pyridine (Sigma-Aldrich,
Dorset,UK) followed by 60 min incubation at 60 °C and subsequently 60 μl N-
tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) with 1% (w/v)
tertbutyldimethyl-chlorosilane (TBDMSCI) (Sigma-Aldrich, Dorset, UK) deriva-
tization reagent was added. The suspension was incubated for an hour at 60 °C in a
well-sealed tube to prevent evaporation. Finally the samples were centrifuged at
13,000 rpm for 5 min and the clear supernatant was transferred to a chromato-
graphy vial with a glass insert (Thermo Fisher, Scientific, Chromacol, Hertford-
shire, UK) and proceeded immediately to GC-MS analysis.
GC-MS/MS analysis. For analysis of the derivatized samples an Agilent 7890B
Series GC/MSD gas chromatograph with a polydimethylsiloxane GC column
coupled, with a mass spectrometer (GC-MS) (Agilent Technologies UK Limited,
Stockport, UK) was used. Prior to sample analysis the GC-MS was tuned to a full
width at half maximum (FWHM) peak width of 0.60 a.m.u. in the mass range of 50
to 650 mass to charge ratio (m/z) using PFTBA tuning solution.
One microlitre of sample was injected into the GC-MS in splitless mode with
helium carrier gas at a rate of 1.0 ml min−1. The inlet liner containing glass wool
was set to a temperature of 270 °C. Oven temperature was set at 100 °C for 1 min
before ramping to 280 °C at a rate of 5 °Cmin−1. Temperature was further ramped
to 320 °C at a rate of 10 °Cmin−1 held at 320 °C for 5 mins. Compound detection
was carried out in full scan mode in the mass range 50–650m/z, with 2–4 scans s−1,
a source temperature of 250 °C, a transfer line temperature of 280 °C and a solvent
delay time of 6.5 min. The injector needle was cleaned with acetonitrile three times
before measurement commencement and three times following every measurement
thereafter. The raw GC-MS data were converted to common data format (CDF)
using the acquisition software and further processing of the isotope data including
isotope correction and mass isotopomer analysis /batch quantification was
performed on metabolite detector software. To determine absolute concentration, a
7 point calibration series covering the mass range of 0–8.46 µM was prepared in
triplicates with 100 µl of 8.5 µM of internal standard added to each sample of the
calibration series and were extracted as the method outlined above. The dried
extract were then derivatised followed by GCMS analysis. For absolute
quantification, the ratio of peak area of each concentration to the peak area of
internal standard was calculated and plotted against the ratio of the concentration of
analyte with respect to the concentration of internal standard to generate the
equation and estimate the linear dynamic range. Subsequently, the raw peak area for
each analyte of interest was calculated using the metabolite detector software
followed by normalizing the response to the internal standard peak area.
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Tissue extraction for 13C NMR. Frozen hearts were weighed and ground to a fine
powder under liquid nitrogen and extracted at 4 °C with 6% perchloric acid (PCA) in
a ration 5:1. The suspension was centrifuged at 4000 RPM, 4 °C for 10min and a
known volume of supernatant decanted and neutralised with 6M KOH to pH7.0 at
4 °C. The mixture was centrifuged and the supernatant lyophilised at −40 °C. Lyo-
philised tissue extracts were reconstituted in 0.6ml of 50mM deuterated phosphate
(KH2PO4) buffer pH 7.0 lyophilised and resuspended in D2O. A small amount of
chelating resin (Chelex-100) was added to samples to remove any paramagnetic ions
and filtered through a 0.22 μm syringe filter into 3mm NMR tube.
High resolution 13C NMR of tissue extracts. High-resolution 1H-decoupled 13C
NMR spectra were acquired under automation at 298 K on a Bruker Avance III 700
(16.4 T) NMR spectrometer (Bruker Biospin, Coventry, UK) equipped with a 5 mm
TCI helium-cooled cryoprobe and a refrigerated SampleJet sample changer. The
temperature was allowed to stabilise for 3 min after insertion into the magnet.
Tuning, matching and shimming was performed automatically for each sample and
the 1H pulse length was calibrated on each sample and was typically around 8 µs.
1D 1H-decoupled 13C spectra (zgpg60) were acquired with 8192 transients, a
spectral width of 200 ppm, 64 K data points, a mixing time of 10 ms, relaxation
delay of 1 s and repetition time of 2 s. 1H-decoupling was achieved using a
WALTZ65 sequence during the relaxation delay and acquisition. Spectra were
processed in the manufacturer’s software (Topspin 3.2.6). Free induction decays
were multiplied with an exponential function (line broadening of 0.25 Hz), Fourier
transformed, phase correction was performed manually and automatic baseline
correction was applied. Representative spectra are shown in Fig. 1b. The relative
contributions of exogenous 13C substrates (palmitate vs glucose) to oxidative
phosphorylation were determined from 13C glutamate isotopomer labelling pat-
terns (Fig. 1b) using tcaCALCtm software (v2.07)22,24.
In silico modelling. In silico simulations were performed using the metabolic net-
work of the cardiomyocyte CardioNet21,22,45. Mathematical modelling has previously
been used to study the dynamics of cardiac metabolism in response to stress20,21,46,
and CardioNet has been successfully applied to identify limiting metabolic processes
and estimate flux distributions20,22. Flux balance analysis (FBA) allows to estimate
flux rates in a cellular model based on metabolic constraints that are defined by the
extracellular environment (e.g. oxygen and nutrient supply), cellular demands (e.g.
proliferation, contraction) and tissue type (e.g. heart vs. liver). This modelling
approach combines biochemical network models with optimality problems, which
describe different cost or benefit functions and allow us to include experimental data,
for example metabolite levels, enzyme levels or flux rates.
The advantage of flux balance analysis is that it considers system-wide effects of
processes and allows us to assess metabolic limitations in an unbiased approach.
We applied flux balance analysis to identify which reactions are involved in
myocardial metabolic adaptations to high levels of Nai.
Mathematical modelling of myocardial metabolic adaptations to Nai eleva-
tion. Metabolic flux distributions were calculated using constrained based mod-
elling. To calculate flux rate changes (vi), we constrained the model for each
metabolite using experimentally determined metabolite concentrations (1H NMR,
LC-MS/MS, effluent lactate production, 13C substrate utilization measurements) to
maximize cardiac work reflected by ATP hydrolysis (vATPase). The decision to
optimize steady-state ATP production was not arbitrary. Our data show that while
Na elevation re-programs metabolism, it does so while not compromising ener-
getics—as demonstrated by our 31P-NMR measurements showing maintained
ATP, PCr, PCr/ATP ratios and pHi. ATP and PCr concentrations are clearly a
product of both production and consumption, however, our wet-biology experi-
mental design tries to keep consumption as constant as possible (by the titration
of contractility with blebbistatin) thereby keeping steady-state ATP consumption
constant. Simulations were run with boundary conditions reflecting the metabolite
composition of the perfusion buffer and experimentally measured uptake and
release rates of substrates. At the same time, various metabolites, including amino
acids and lipids, were set to previously reported values21,47–49, in order to mimic
the ex vivo experimental conditions. Based on these constrains we first determined
flux distributions (vm) under baseline control conditions. We then calculated fold-
changes (FC) for experimentally measured metabolite concentrations between
baseline controls and treatment groups (acute and chronic Nai elevation), and used
these FC to further constrain fluxes (vm) for the synthesis and/or degradation of
intracellular metabolites. We included FC based on the assumption that changes in
metabolite concentrations under experimental conditions are accompanied by a
proportional increase or decrease in the respective flux for the metabolite pool. By
using metabolite level changes (fold changes) to estimate flux rate changes (vFC),
we imply that the altered steady-state concentrations of metabolites are reflected in
the newly evolved flux state and potentially limit metabolic functions.
The following flux balance analysis was applied to identify steady-state flux
distributions that are in agreement with applied substrate uptake and release rates,
and changes in metabolite pools:
max vATPase ð1Þ
subject to (1)
S  v ¼ 0; ð2Þ
vðÞi ≤ vi ≤ v
þð Þ
i ; ð3Þ
LðÞj ≤ vj ≤ L
þð Þ
j j ¼ j1; j2; ¼ð Þ; ð4Þ
vm ≤ FCm  v0m m ¼ m1; m2; ¼ð Þ; ð5Þ
where vi denotes the flux rate change through reaction i, vj denotes the measured
uptake or secretion rate through reaction j, S is the stoichiometric matrix, and vðÞi
and vðþÞi are flux constraints. The CPLEX LP solver was used to find the solution
to the FBA problems. The logarithm of the metabolic flux rate values is presented
in the form of heatmaps. Metabolic reactions are clustered according to their
association to metabolic pathways and plot colours indicate estimated flux rates for
each metabolic reaction. All reactions and their metabolic subsystems, classified in
the Kyoto Encyclopedia of Genes and Genomes database50.
Data statistics and reproducibility. Data are presented as mean ± SEM and
analysed blind to phenotype or treatment. Statistical analysis was conducted using
GraphPad Prism (v 8.3) and Microsoft Excel (v.16.16.15). All data were obtained
from a minimum of two independent experiments. Comparison between groups
was by Student’s t-test (Gaussian data distribution), two-way analysis of variance
(ANOVA) with Bonferroni’s correction for multiple comparison and one-way
ANOVA using Bonferroni’s correction for multiple comparisons where applicable.
After pharmacological agent treatment (ouabain, blebbistatin, CGP13757), hearts
were compared to baseline control values for the same genotype. Metabolite fold
changes of the ratio of treated (T) vs control (C) groups were calculated and the
fold change. Propagated standard error (SEM) of the ratio was calculated using the
formula SEMðT=CÞ ¼ ðT=CÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðSEMT=TÞ2 þ ðSEMC=CÞ2
q
, assuming the covariance
between the two groups is zero, i.e., C and T are uncorrelated. Metabolic differences
between the flux distributions were analysed by R Statistics (version 1.2.1335 for
Fedora/RatHat 7 64-bit, R version 3.0.1, Boston Massachusetts, USA, www.rstudio.
com)51. Datasets were tested for normal distribution using the Shapiro–Wilk test.
Groups were compared using non-parametric (Kruskal–Wallis) test methods.
Unsupervised hierarchical clustering and PCA were conducted using R-Studio.
Heat maps and z-scores were generated using R-Studio with the heatmap.2 func-
tion and viridis colour palettes from the R-package gplots (version 3.0.1.1)
Z-scores were calculated as follows:
z ¼ ðX  μÞ
σ
ð6Þ
where z denotes the z-score, X is the average flux rate for a given reaction within an
experimental group (control, acute and chronic Na elevation), μ is the population
mean, σ and is the standard deviation. Z-scores were calculated for each reaction
(each row in the heat map) including all control, acute and chronic Na elevation
values. Each calculated z-score was assigned a colour as depicted in the heat map.
The similarity between groups was assessed using a Euclidean distance and the
number of clusters was determined using the k-means algorithm. We applied the
Elbow method to determine optimal numbers of clusters. Columns (experimental
groups) were clustered hierarchically according to dissimilarities between clusters
with the squared Euclidean distances between cluster means calculated.
Differences were considered significant when P < 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data supporting the results presented herein are available from the corresponding
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